JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Inicio・Lista de Acciones・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Cerrado

SectorSalud

24.73 -2.21

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

24.16

Máximo

25.36

Métricas clave
By Trading Economics
Ingresos	9.2M -16M
Ventas	16M 82M
Margen de beneficio	-19.491
Empleados	342
EBITDA	6.7M -12M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+8.93% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	680M 2.4B
Apertura anterior	26.94
Cierre anterior	24.73

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

133 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

12.42 / 14.93 Soporte y Resistencia

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 nov 2025, 22:13 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov 2025, 21:23 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov 2025, 23:43 UTC

Charlas de Mercado

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov 2025, 23:34 UTC

Charlas de Mercado

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov 2025, 20:45 UTC

Ganancias

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov 2025, 20:44 UTC

Ganancias

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov 2025, 20:43 UTC

Ganancias

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov 2025, 20:42 UTC

Ganancias

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov 2025, 20:41 UTC

Ganancias

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov 2025, 20:40 UTC

Ganancias

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov 2025, 20:39 UTC

Ganancias

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov 2025, 20:36 UTC

Ganancias

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov 2025, 20:34 UTC

Ganancias

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov 2025, 20:33 UTC

Ganancias

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov 2025, 14:27 UTC

Ganancias

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov 2025, 14:25 UTC

Ganancias

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

8.93% repunte

Estimación a 12 meses

Media 27.57 USD 8.93%

Máximo 32 USD

Mínimo 21 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimiento

By Acuity

133 / 373 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.